Predicting Response Trajectories during Cognitive-Behavioural Therapy for Panic Disorder: No Association with the BDNF Gene or Childhood Maltreatment

Martí Santacana1,2, Bárbara Arias3,4, Marina Mitjans4,5, Albert Bonillo6, María Montoro1, Silvia Rosado7, Roser Guillamat1, Vicenç Vallès1, Víctor Pérez4,7, Carlos G. Forero8,9,10*, Miquel A. Fullana2,7*

1 Department of Mental Health, Consorci Sanitari de Terrassa, Terrassa, Spain, 2 Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain, 3 Anthropology Unit, Department of Animal Biology, Universitat de Barcelona, Barcelona, Spain, 4 CIBERSAM (Centro de Investigaciones Biomédicas en Red de Salud Mental), Instituto de Salud Carlos III, Madrid, Spain, 5 Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany, 6 Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain, 7 Institute of Neuropsychiatry and Addictions, Hospital del Mar, Barcelona, Spain, 8 CIBERESP (Centro de Investigaciones Biomédicas en Red, Epidemiología y Salud Pública), Instituto de Salud Carlos III, Madrid, Spain, 9 Health Services Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain, 10 Department of Experimental and Life Sciences (DCEXS), Universitat Pompeu Fabra, Barcelona, Spain

* miguelangelfullana@gmail.com (MAF); cgarcia@imim.es (CGF)

Abstract

Background

Anxiety disorders are highly prevalent and result in low quality of life and a high social and economic cost. The efficacy of cognitive-behavioural therapy (CBT) for anxiety disorders is well established, but a substantial proportion of patients do not respond to this treatment. Understanding which genetic and environmental factors are responsible for this differential response to treatment is a key step towards “personalized medicine”. Based on previous research, our objective was to test whether the BDNF Val66Met polymorphism and/or childhood maltreatment are associated with response trajectories during exposure-based CBT for panic disorder (PD).

Method

We used Growth Mixture Modeling to identify latent classes of change (response trajectories) in patients with PD (N = 97) who underwent group manualized exposure-based CBT. We conducted logistic regression to investigate the effect on these trajectories of the BDNF Val66Met polymorphism and two different types of childhood maltreatment, abuse and neglect.

Results

We identified two response trajectories (“high response” and “low response”), and found that they were not significantly associated with either the genetic (BDNF Val66Met
polymorphism) or childhood trauma-related variables of interest, nor with an interaction between these variables.

Conclusions
We found no evidence to support an effect of the BDNF gene or childhood trauma-related variables on CBT outcome in PD. Future studies in this field may benefit from looking at other genotypes or using different (e.g. whole-genome) approaches.

Introduction
The high prevalence of the anxiety disorders is a major public health concern. Twelve-month prevalence rates have been estimated at 18.1% in the US [1] and 13.6% in Europe [2]. In addition, anxiety disorders have a marked impact on the quality of life of those affected [3], and cause a huge social and economic burden. At the European level, Olesen et al. [4] quantified the total annual cost of anxiety disorders as 74.4 billion euros.

The efficacy of cognitive-behavioural therapy (CBT) for anxiety disorders is well established from randomised controlled trials [5], and is recommended by current clinical guidelines [6, 7]. However, a substantial proportion of patients do not respond to this treatment [8], and identifying the factors underlying this differential treatment response is now a research priority. In this context, genetic and environmental predictors of outcome have gained attention [9, 10] and will make a key contribution towards “personalized medicine” [11]. However, it remains to be tested whether results of basic research can be translated into clinical practice.

The prediction of treatment response based on genetic background has a long history in pharmacotherapy, but is a relatively new development in the field of psychological treatment. The term “therapygenetics” was coined a few years ago to indicate the prediction of psychological treatment outcomes from genetic markers [10, 12, 13]. Most research in this area has focused on testing the effects of specific single nucleotide polymorphisms (SNP) on response to CBT in anxiety and depressive disorders. Although the field is in its infancy, initial evidence indicates that specific SNPs may improve the prediction of CBT outcomes (i.e. a decrease in measures of severity). The most widely assessed SNP have been the serotonin transporter gene functional length polymorphism (5HTTLPR), and the functional Val66Met (rs6265) polymorphism in the brain-derived neurotrophic factor (BDNF) gene [9, 10].

Both preclinical and clinical data suggest that Val66Met is involved in response to CBT (and more specifically, to exposure-based interventions) for anxiety and related disorders. Val66Met, which involves substitution of valine (Val) with methionine (Met), affects intracellular trafficking and secretion of BDNF, and Met carriers show decreased activity-dependent secretion of this neurotrophin [14]. Consistent with animal studies, this variation may be associated with anxiety or fear in humans [15]. Recent research suggests that extinction learning, which is the experimental model for exposure therapy, may be modulated by genetic variation in BDNF, and both mouse and human carriers of the Met variant show impaired extinction learning [16]. Moreover, humans carriers show a different pattern of activation of brain regions that are essential for fear extinction (including the ventromedial prefrontal cortex and the amygdala), which is consistent with impaired extinction learning [16, 17]. Preliminary translation of these basic results is provided by two recent studies showing that among adults with post-traumatic stress disorder (PTSD) [18] and obsessive-compulsive disorder (OCD) [19], those with the Met allele had a poorer response to exposure-based CBT than those with the
Val/Val genotype. However, this association was not replicated in a study in adults with social anxiety disorder (SAD) who received internet-based or group CBT [20], or in a study in children with mixed anxiety disorders who were receiving CBT [21].

Regarding environmental factors, childhood maltreatment has been the focus of extensive research. Beyond its established role as a risk factor for many mental disorders [22, 23], childhood maltreatment may also influence treatment outcomes. There is a well established association between childhood maltreatment and poor response to treatment for depression, and this association seems to be independent of treatment modality (pharmacological or psychological) [24]. However, this issue has not been investigated in detail for anxiety disorders, and very few studies have considered whether specific forms of maltreatment are relevant. To our knowledge, only two studies in patients with SAD have examined the impact of specific types of childhood maltreatment on CBT outcomes in anxiety disorders [25, 26]. Alden et al. [25] found that parental abuse increased risk of poor treatment outcome, while Bruce et al. [26] found no association between specific types of childhood maltreatment and response to CBT.

There has been at least one preliminary attempt to combine genetic and clinical variables to predict outcomes of psychological treatment in children with anxiety disorders [9]. To our knowledge, however, the role of genetics and early developmental experiences such as maltreatment in predicting the outcome of CBT in adults has not yet been explored.

Our aim was to study whether the BDNF Val66Met polymorphism and/or childhood maltreatment were associated with the outcome of exposure-based CBT for panic disorder (PD) in a naturalistic setting. Based on growth mixture models (GMM), we operationalized treatment outcome with trajectories of change in panic symptoms. Trajectory analyses have recently been used in psychological treatment research to identify patterns of change and to examine treatment effects in different patients subgroups [27–32]. This approach has several methodological advantages and is probably more clinically informative [28, 30, 33, 34].

Based on previous research, we predicted the existence of distinct response trajectories in patients receiving exposure-based CBT, and we hypothesised that genetic variation (presence of the BDNF Met allele) and childhood maltreatment (both abuse and neglect) would be associated with a less favourable response trajectory.

**Method**

**Participants**

Our sample consisted of 97 patients who completed (i.e., attended ≥ 8 sessions) a 9-week intervention of manualized exposure-based group CBT (GCBT) for PD at one of two treatment centres in Barcelona (Spain) between February 2011 and January 2014. During the recruitment period, 132 patients were assessed, and the following exclusion criteria were applied: age <18 or >60 years; presence or history of any organic mental disorder, bipolar disorder or psychosis; substance abuse or dependence in the previous three months (except for nicotine); intellectual disability; and language barriers. A Consort flow diagram of the recruitment process is shown in Fig 1.

All participants had a primary diagnosis of PD (89.7% with agoraphobia) according to the DSM-IV-TR [35], and had a score of ≥6 on the Spanish self-report version [36] of the Panic Disorder Severity Scale (PDSS-SR) [37]. Diagnosis was established by one experienced clinician using a semi-structured interview, and was confirmed by another clinician using the validated Spanish version [38] of the Mini International Neuropsychiatric Interview (MINI) [39].

The final sample included 61 women (62.9%), and the mean age was 36.19 years (range 18–60, SD = 9.23). Twenty-two participants (22.7%) presented one or more additional axis-I disorders. The most common comorbidities were SAD (7.2%), specific phobia (6.2%), generalized...
Fig 1. Consort flow diagram.

doi:10.1371/journal.pone.0158224.g001
anxiety disorder (3.1%), and others (6.2%). On admission, eighty-two patients (84.5%) were taking psychiatric medication (mainly antidepressants) continually for at least two months prior to beginning treatment, and 40 (41.2%) were taking PRN benzodiazepines. Participants were asked to maintain their medication regime during the GCBT. Table 1 shows a demographic and clinical summary of the sample.

The study fulfilled the principles of the World Medical Association Declaration of Helsinki and was approved by the Clinical Research Ethical Committee of the Parc de Salut Mar (Barcelona, Spain) and by the Clinical Research Ethical Committee of the Consorci Sanitari de Terrassa (Barcelona, Spain). All participants provided voluntary informed written consent.

**Assessment**

The MINI (Spanish version 5.0.0) is a brief structured interview that evaluates the presence of Axis I disorders according to DSM-IV criteria [39], and is a widely used instrument in clinical and research settings. The Spanish version of the MINI has shown to have sound psychometric properties [40].

Table 1. Demographic and clinical characteristics of the sample (N = 97).

|                         | % / Mean (sd) |
|-------------------------|---------------|
| **Gender**              |               |
| Men                     | 37.1%         |
| Women                   | 62.9%         |
| **Age (years)**         | 36.19 (9.23)  |
| **Marital status**      |               |
| Single                  | 30.5%         |
| Married/in a relationship | 69.5%     |
| **Education level**     |               |
| Elementary school       | 28.4%         |
| High school             | 45.3%         |
| University              | 26.3%         |
| **Unemployed**          | 45.8%         |
| **Age of onset (panic symptoms)** | 25.58 (9.13) |
| **Duration of current episode (in years)** | 4.13 (5.58) |
| **Presence of agoraphobia** | 89.7%       |
| **Axis-I comorbidity**  | 22.7%         |
| **Pharmacological treatment** |           |
| No medication           | 15.5%         |
| Antidepressant + benzodiazepine | 41.2% |
| Antidepressant          | 19.6%         |
| Benzodiazepine          | 23.7%         |
| **BDNF Val66Met genotypes** |         |
| Val-Val                 | 61.9%         |
| Met carriers            | 38.1%         |
| **CTQ-SF scores**       |               |
| Emotional abuse         | 9.64 (5.24)   |
| Physical abuse          | 6.44 (3.30)   |
| Sexual abuse            | 5.69 (1.56)   |
| Emotional neglect       | 10.66 (4.82)  |
| Physical neglect        | 6.59 (2.46)   |

M = mean, sd = standard deviation, CTQ-SF = Childhood Trauma Questionnaire-Short Form

doi:10.1371/journal.pone.0158224.t001
The self-report version of the Panic Disorder Severity Scale (PDSS-SR) is a 7-item instrument that assesses the frequency of panic attacks, associated distress, anticipatory anxiety, agoraphobic fear and avoidance, body-sensation fear and avoidance, and impaired work and social function [37] during the previous week. Each item is scored on a 5-point ordinal scale (0–4), and the total score ranges between 0 and 28. The Spanish PDSS-SR has shown excellent internal consistency, good test-retest reliability, adequate convergent and divergent validity, and good sensitivity to change [36].

The Childhood Trauma Questionnaire-Short Form (CTQ-SF) is a 28-item instrument that measures five types of childhood maltreatment: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect [41, 42]. Each item ranges from 1 to 5, and the total score of each subscale ranges from 5 to 25. Following previous research [43], childhood maltreatment was grouped into two main types: childhood abuse (including emotional, physical and sexual abuse) and childhood neglect (including emotional and physical neglect). Childhood abuse and childhood neglect were calculated by summing the items of the corresponding subscales. The Spanish CTQ-SF has been shown to be a reliable and valid instrument [44].

**Treatment**

Group CBT consisted of nine one-hour sessions administered on a weekly basis. Groups were conducted by a main therapist (a PhD level clinical psychologist) and a co-therapist (a clinical psychology trainee or psychiatric nurse), and ranged from 4 to 7 patients each. Treatment was manualized and the protocol was a modified version of the Panic Control Treatment by Barlow and Craske [45], adapted by the last author. Sessions 1 to 3 were devoted to education about anxiety and panic; sessions 4 and 5 consisted of in-session interoceptive exposure exercises, and progressive withdrawal of safety behaviors; and sessions 6 to 9 focused on graded exposure to avoided situations and activities. The treatment included homework exercises that varied depending on the phase of therapy, and did not include specific cognitive therapy tasks. To maximize treatment integrity and adherence to the protocol, fortnightly meetings between the main therapists were scheduled and checklists with the items to be covered at each session were provided to the co-therapists. Thirty-nine patients (40.2%) had at least one individual “booster” session during the six month follow-up period. Previous research has established the effectiveness of this treatment protocol [46].

**Procedure**

At the beginning of each session and at one, three and six months follow-up, participants completed the PDSS-SR to assess panic symptoms during the previous week. Additionally, participants also completed the CTQ-SF during the initial assessment session.

**Genetic analyses**

Genomic DNA was extracted from buccal mucosa on a cotton swab, or from blood samples using the Real Extraction DNA Kit (Durviz S.L.U., Valencia, Spain). The rs6265 SNP (Val66-Met) of the BDNF gene was determined using the Taqman 5’ exonuclease assay -Applied Biosystems (AB)- and genotyped using AB TaqMan technology. The probe for genotyping the rs6265 was ordered through the TaqMan SNP Genotyping assays AB assay-on-demand service (code C_11592758_10). The final volume of the polymerase chain reaction (PCR) reaction was 5 mL, which contained 10 ng of genomic DNA, 2.5 ml of TaqMan Master Mix, and 0.125 ml of 40x genotyping assay. The cycling parameters were as follows: 95°C for 10 min, followed by 40 cycles of denaturation at 92°C for 15 s and annealing/extension at 60°C for 1 min. PCR plates
were read on an ABI PRISM 7900HT instrument with SDS v2.1 software (AB). The genotype frequencies of rs6265-BDNF were in Hardy-Weinberg equilibrium ($\chi^2 = 0.53; p = 0.467$).

**Statistical analyses**

In the first step, we used growth mixture models (GMM) analysis to empirically identify latent subpopulations of patients with similar change trajectories ('trajectory classes') in panic symptoms, as measured using the PDSS-SR (baseline, plus 9 weekly ratings, plus three follow-up sessions). In GMM, trajectory classes are characterized by two parameters: intercept (i.e. initial severity) and slope (i.e. rate of change). GMM allows us to test for an a priori unknown number of latent subpopulations with different intercepts and slopes, as well as class-specific variations around these parameters.

To determine the optimal number of trajectory classes, we compared different linear models, starting with a one-class model (i.e. assuming that all participants followed the same trajectory) and then adding classes in each subsequent run. For each model, allocation of individuals was based on maximum posterior probability [47]. Models were estimated with 2000 random starting values, using MPLUS software (version 7.0). To decide on the number of trajectory classes, we examined the following indices of goodness of fit: Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), sample-size adjusted BIC (SSBIC) and the bootstrap likelihood ratio test (BLRT). The model with the lowest SSBIC was chosen [48]. The BLRT was used to assess differences in log-likelihood between models with k and k+1 classes, where p<0.05 indicates the benefit of adding an additional class [49]. We also computed the entropy value for each class solution. In addition to the indices of goodness of fit, the optimal number of latent trajectory classes was also based on group membership posterior probabilities, distinctiveness of classes and how well the PDSS-SR profiles of subjects from one class matched the class average. For all intercept and slope coefficients, we report unstandardized coefficients.

In the second step of the analyses, we conducted logistic regression analysis to test whether genetic background (presence/absence of the BDNF 66Met allele) and trauma-related variables (childhood abuse and childhood neglect) predicted class membership. To control for the potential effect of pharmacological treatment, this variable was included in the model as a covariate. Finally, the model also included variables for interaction effects between childhood abuse and BDNF genotype, and between childhood neglect and BDNF genotype.

**Results**

**Genetic and trauma-related variables**

Carriers of one or two BDNF66Met alleles were combined as a “Met-carrier group”, consistent with previous studies [18, 19, 50]. The genotype frequencies for the BDNF Val66Met polymorphism were: 31.8% (N = 37) Met allele carriers (including 6 Met/Met homozygotes), and 61.9% (N = 60) Val-Val homozygotes. In line with previous reports [51–53], we evaluated the prevalence of childhood maltreatment was evaluated using the following cut-off scores: emotional abuse ≥9, physical abuse ≥8, sexual abuse ≥6, emotional neglect ≥10 and physical neglect ≥8. In the current sample, 53 participants (55.2%) had been exposed to at least one type (emotional, physical, or sexual) of childhood abuse, and 51 (53.7%) to at least one type (emotional or physical) of childhood neglect.

**Identification of trajectory classes**

Preliminary sensitivity analyses showed that the models including and excluding participants with more than 3 missing data points gave the same class structures. Since missing data did not
affect results substantially, two participants with missing data were excluded, leaving 95 participants for the trajectory analyses.

Table 2 shows the fit indices for models with 1 to 3 trajectory classes for the PDSS-SR. BLRT was only significant in the change between the 1-class and the 2-class models, which was not significantly different to the 3-class model. The 2-class solution was therefore selected because it had the lowest SSBIC and a high entropy, which was 0.85, over the recommended cut-off of 0.80 [54].

Fig 2 shows that one class ("high response") included patients (N = 76; 80.3% of the sample) with lower baseline panic symptoms (intercept = 12.12, SE = 2.06, \( p < 0.01 \)) and a tendency to improve over time (slope = -0.329, SE = 0.12, \( p = 0.01 \)). The other class ("low response") included patients (N = 19; 19.7% of the sample) with greater panic symptoms at baseline.
(intercept = 18.36, SE = 2.76, \( p<0.01 \)) and which did not improve across time (slope = -0.17, SE = 0.15, \( p = 0.26 \)).

Effects of genetic background and trauma on trajectory classes

Table 3 shows that neither the \textit{BDNF} Val66Met polymorphism nor the specific types of trauma analysed (abuse and neglect) predicted membership of any specific trajectory class. We found no significant evidence to suggest that trajectory class membership was affected by gene-environment interaction between the \textit{BDNF} Met allele and childhood abuse, nor between the \textit{BDNF} Met allele and childhood neglect.

Discussion

To our knowledge, this is the first study to evaluate the effects of the \textit{BDNF} Val66Met polymorphism and childhood maltreatment as possible predictors of CBT outcome in PD (assessed using trajectories of change). We found no evidence that either \textit{BDNF} Val66Met or childhood maltreatment were significant predictors of CBT outcome.

In our sample PD patients followed two different trajectories during treatment. Many patients (80.3\%) showed a tendency to improve as a result of CBT, whereas a significant proportion (19.7\%) did not. While there is a general paucity of data on trajectories of change during CBT for PD, our results are consistent with data from a previous study that highlighted a group of PD patients with high baseline symptoms that tend not to improve with CBT [28]. We observed a similar percentage of patients with this non-remitting course (19.7\%) to that reported by Lutz et al. (17.2\%).

We did not find a significant association between the \textit{BDNF} Val66Met polymorphism and CBT treatment outcome. In light of previous reports, our results show that there is no compelling evidence to suggest that this genetic variation can be used to predict response to exposure-based CBT. In previous studies in adults, PTSD [18] and OCD patients [19] who carried the Met allele showed a poorer response than Val/Val homozygotes, although effects of \textit{BDNF} in the OCD study were apparent in the percentage of responders, but not in the pre- to post-treatment severity scores. In addition, no association has been found between the \textit{BDNF} Met allele and CBT outcome in SAD [20] or in mixed child anxiety disorders [21]. Thus, based on ours and previous studies, it seems that the relatively well established association between the \textit{BDNF} gene and learning and memory, and specifically with fear extinction [16, 55], does not translate easily into clinical practice. One possible explanation is that the BNDF effect may be observed in very controlled experiments, but may be diluted among the multiple variables involved in clinical studies [56]. In an extensive review of the association between the \textit{BDNF} Val66Met
polymorphism and mental disorders, Notaras and van den Buuse [57] highlight some of the possible methodological shortcomings as an explanation for previous inconsistent results, including small sample sizes and ethnicity-specific effects. It may also be the case that the BDNF gene provokes a poorer response in some anxiety-related disorders but not in others. For example, Hedman et al. [12] have recently proposed that exposure might have a more decisive role in some anxiety-related disorders (e.g., PTSD) than in others (e.g., SAD).

Another possibility is that other polymorphisms (rather than the one studied here) may be more important for predicting CBT outcome. A recent large study (N = 829) did not replicate the previously reported association [12] between the functional serotonin transporter promoter polymorphism and CBT outcome [58]. The authors of this study recommended abandoning the single-variant approach and moving towards a whole-genome array-based therapygenomics approach. A recent study from the same group also found no evidence of an effect of hypothalamic-pituitary-adrenal axis-related genes on response to CBT [59]. These authors also investigated epigenetic factors (changes in DNA methylation) and suggested that epigenetic variables may be a better predictor of CBT outcome than genetic factors. Regardless, it would be necessary to evaluate the clinical relevance of any positive association between (epi)genetic variation and psychological treatment [21].

We also found no evidence to suggest that childhood abuse and childhood neglect predict CBT outcome. Only two previous studies have investigated the effects of childhood maltreatment on CBT outcome in anxiety disorders, specifically in SAD patients [25, 26]. Bruce et al. did not find an association between childhood maltreatment and CBT outcome, as Alden et al. had previously observed. However, in the study by Bruce et al., the patients who reported emotional abuse, emotional neglect and sexual abuse showed greater severity before and throughout treatment. Here, we focused on symptom reduction as our index of CBT outcome, and it remains possible that other variables (e.g. attrition rates or relapse/recurrence rates) may be affected by childhood abuse/neglect. Future studies that include these and other treatment-related outcomes may provide additional insights.

Finally, we detected no interaction between the polymorphism of interest and childhood abuse or neglect. As suggested by Keers et al. [60], inconsistent findings in previous studies on stressful life events may be due to unmeasured genetic moderators. Again, epigenetic factors have recently been identified in individuals with a history of abuse [61] and in institutionalized children [62], and it would be interesting for future studies to add epigenetics to the prediction of psychological treatment outcomes.

Several limitations of this study should be noted. First, a limitation of reporting negative results is that they could be due to a lack of statistical power rather than a real lack of effect in the population. However, the present study reports on a larger or similar sample (N = 97) than several previous studies that have found significant effects of genetic polymorphisms (the BDNF Val66Met and others) on the psychological [18, 19, 63] or pharmacological treatment [64, 65, 66] of anxiety and related disorders. Our sample is also much larger than a previous study that did find an effect of childhood maltreatment on CBT outcome [25]. A formal estimate of power in our study was hampered by the fact that we measured the effects of treatment using response trajectories, and the previous literature could not offer sufficient guidance to provide such calculations. Be as it is, one possibility to increase the sample size in future studies would be to include patients with different anxiety-related diagnoses and/or using different CBT modalities. This strategy was followed in Lester et al. [58], where children with mixed anxiety disorders receiving individual CBT, group-based CBT or parent-supported guided self-help were included. Second, most of the patients were receiving pharmacological treatment during CBT. While medication was kept stable for at least two months before the treatment started, we cannot exclude the possibility that improvement in panic symptoms was due to
maintaining pharmacotherapy over time. However, this was controlled for by including drug treatment as a covariate in our analyses. Third, our sample consisted mainly of non-responders to pharmacotherapy, which could represent a subgroup with different (including genetic) characteristics than the entire spectrum of patients with PD. Fourth, due to the low frequency of the BDNF Met allele in the European population [67], our Met/Met group was too small to be tested. Fifth, although we accounted for some environmental factors, the BDNF Val66Met polymorphism is unlikely to adhere to a simple genetic model [57], and so future studies involving genetic combinations may be warranted.

In conclusion, we found no evidence to support the effect of either the BDNF Val66Met polymorphism or childhood trauma-related variables on CBT outcome. Future studies that address the role of other (including epigenetic) variables may shed light on the neurobiological prediction of psychological treatment outcomes.

Supporting Information
S1 Fig. Mean scores of the PDSS-SR throughout the treatment and follow-up for Met-carriers and Val-Val.
(JPG)

Author Contributions
Conceived and designed the experiments: MS BA MAF. Performed the experiments: MS M. Mitjans M. Montoro SR MAF. Analyzed the data: MS BA AB CGF. Wrote the paper: MS CGF MAF. Critical revision of the manuscript for important intellectual content: BA CGF. Final approval of the version to be published: BA AB RG VV VP CGF.

References
1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62: 617–27. PMID: 15939839
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;( 420): 21–7. PMID: 15128384
3. Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. J Consult Clin Psychol. 2014; 82: 375–91. doi: 10.1037/a0035491 PMID: 24447006
4. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B; CDBE2010 study group, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012; 19: 155–62. doi: 10.1111/j.1468-1331.2011.03590.x PMID: 22175760
5. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008; 69: 621–32. PMID: 18363421
6. American Psychiatric Association. PsychiatryOnline [Internet]. Place unknown: American Psychiatric Association Publishing; date unknown [Accessed 2 Mar 2016]. Available: http://psychiatryonline.org/guidelines
7. National Institute for Health and Care Excellence. NICE Guidance [Internet]. Place unknown: National Institute for Health and Care Excellence; c2016 [Accessed 2 Mar 2016]. Available: http://www.nice.org.uk/guidance
8. Loerinc AG, Meuret AE, Twohig MP, Rosenfield D, Bluett EJ, Craske MG. Response rates for CBT for anxiety disorders: Need for standardized criteria. Clin Psychol Rev. 2015; 42: 72–82. doi: 10.1016/j.cpr.2015.08.004 PMID: 26319194
9. Hudson JL, Lester KJ, Lewis CM, Tropeano M, Creswell C, Collier DA, et al. Predicting outcomes following cognitive behaviour therapy in child anxiety disorders: the influence of genetic, demographic and clinical information. J Child Psychol Psychiatry. 2013; 54: 1086–94. doi: 10.1111/jcpp.12092 PMID: 23772677
10. Lester KJ, Eley TC. Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord. 2013; 3: 4. doi: 10.1186/2045-5380-3-4 PMID: 23388219

11. National Institute of Health. National Institute of Mental Health Strategic Plan for Research [Internet]. Place unknown: National Institute of Health; 2015 [Accessed 2 Mar 2016]. Available: http://www.nimh.nih.gov/about/strategic-planning-reports/nimh_strategicplanforresearch_508compliant_corrected_final_149979.pdf

12. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P, et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry. 2012; 17: 236–7. doi: 10.1038/mp.2011.132 PMID: 22024766

13. Eley TC. The future of therapygenetics: where will studies predicting psychological treatment response from genomic markers lead? Depress Anxiety. 2014; 31: 617–20. doi: 10.1002/da.22292 PMID: 25044231

14. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004; 24: 4401–11. PMID: 15128854

15. Domingos da Silveira da Luz AC, Pereira Dias G, Bevilaqua MC do Nascimento, Cocks G, Gardino PF, Thuret S, et al. Translational findings on brain-derived neurotrophic factor and anxiety: contributions from basic research to clinical practice. Neuropsychobiology. 2013; 68: 129–38. doi: 10.1159/000353269 PMID: 24051499

16. Soliman F, Giatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science. 2010; 327: 863–6. doi: 10.1126/science.1181886 PMID: 20075215

17. Lonsdorf TB, Golkar A, Lindstrom KM, Haaker J, Ohman A, Schalling M, et al. BDNFVal66Met affects neural activation pattern during fear conditioning and 24 h delayed fear recall. Soc Cogn Affect Neurosci. 2015; 10: 64–71. doi: 10.1093/scan/nau102 PMID: 25193087

18. Felmingham KL, Dobson-Stone C, Schofield PR, Quirk GJ, Bryant RA. The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry. 2013; 73: 1059–63. doi: 10.1016/j.biopsych.2012.10.033 PMID: 23312562

19. Fullana MA, Alonso P, Gratacos M, Jaurrieta N, Jimenez-Murcia S, Segalas C, et al. Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder. Eur Psychiatry. 2012; 27: 386–90. doi: 10.1016/j.eurpsy.2011.09.005 PMID: 22153752

20. Hedman E, Andersson E, Ljotsson B, Andersson G, Andersson E, Schalling M, et al. Clinical and genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta Psychiatr Scand. 2012; 126: 126–38. doi: 10.1111/j.1600-0447.2012.01834.x PMID: 22320999

21. Lester KJ, Hudson JL, Tropeano M, Creswell C, Collier DA, Farmer A, et al. Neurotrophic gene polymorphisms and response to psychological therapy. Transl Psychiatry. 2012; 2: e108. doi: 10.1038/tp.2012.33 PMID: 22932952

22. Hovens JG, Giltay EJ, van Hemert AM, Penninx BW. Childhood Maltreatment and the Course of Depressive and Anxiety Disorders: The Contribution of Personal Characteristics. Depress Anxiety. 2016; 33: 27–34. doi: 10.1002/da.22429 PMID: 26418232

23. Lereya ST, Copeland WE, Costello EJ, Wolke D. Adult mental health consequences of peer bullying and maltreatment in childhood: two cohorts in two countries. Lancet Psychiatry. 2015; 2: 524–31. doi: 10.1016/S2215-0366(15)00165-0 PMID: 26360448

24. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 2012; 169: 141–51. PMID: 22420036

25. Alden LE, Taylor CT, Laposa JM, Mellings TMB. Impact of social developmental experiences on cognitive-behavioral therapy for generalized social phobia. J Cogn Psychother. 2006; 20: 7–16.

26. Bruce LC, Heimberg RG, Goldin PR, Gross JJ. Childhood maltreatment and response to cognitive behavioral therapy among individuals with social anxiety disorder. Depress Anxiety. 2013; 30: 662–9. doi: 10.1002/da.22112 PMID: 23954194

27. Wardenaar KJ, Conradi HJ, de Jonge P. Data-driven course trajectories in primary care patients with major depressive disorder. Depress Anxiety. 2014; 31: 778–86. doi: 10.1002/da.22228 PMID: 24398682

28. Lutz W, Hofmann SG, Rubel J, Boswell JF, Mott MK, Gorman JM, et al. Patterns of early change and their relationship to outcome and early treatment termination in patients with panic disorder. J Consult Clin Psychol. 2014; 82: 287–97. doi: 10.1037/a0035535 PMID: 24447004
29. Joesch JM, Golinelli D, Sherbourne CD, Sullivan G, Stein MB, Craske MG, et al. Trajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary care. Depress Anxiety. 2013; 30: 1099–106. doi: 10.1002/da.22149 PMID: 23801589

30. Stulz N, Thase ME, Klein DN, Manber R, Crits-Christoph P. Differential effects of treatments for chronic depression: a latent growth model reanalysis. J Consult Clin Psychol. 2010; 78: 409–19. doi: 10.1037/a0019267 PMID: 20515216

31. Stulz N, Lutz W. Multidimensional patterns of change in outpatient psychotherapy: the phase model revisited. J Clin Psychol. 2007; 63: 817–33. PMID: 17674397

32. Sunderland M, Wong N, Hilvert-Bruce Z, Andrews G. Investigating trajectories of change in psychological distress amongst patients with depression and generalised anxiety disorder treated with internet cognitive behavioural therapy. Behav Res Ther. 2012; 50: 374–80. doi: 10.1016/j.brat.2012.03.005 PMID: 22498311

33. Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014; 65: 205–10. doi: 10.1159/000362022 PMID: 25413659

34. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010; 6: 109–38. doi: 10.1146/annurev.clinpsy.121208.131413 PMID: 20192788

35. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.

36. Santacana M, Fullana MA, Bonillo A, Morales M, Montoro M, Rosado S, et al. Psychometric properties of the Spanish self-report version of the panic disorder severity scale. Compr Psychiatry. 2014; 55: 1467–72. doi: 10.1016/j.comppsych.2014.04.007 PMID: 24850072

37. Houck PR, Spiegel DA, Shear MK, Rucci P. Reliability of the self-report version of the panic disorder severity scale. Depress Anxiety. 2002; 15: 183–5. PMID: 12112724

38. Bobes J, García-Portilla MP, Bascarán MT, Sáiz PA, Bousoño M. Banco de instrumentos básicos para la práctica de la psiquiatría clínica (Collection of basic tools for the practice of clinical psychiatry). 2nd ed. Barcelona, Spain: Psiquiatría Editores; 2002.

39. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20): 22–33. PMID: 9881538

40. Bobes J. A Spanish validation study of the Mini International Neuropsychiatric Interview. Eur Psychiatry. 1998; 13: 198–9. doi: 10.1016/S0924-9338(98)80004-7

41. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry. 1994; 151: 1132–6. PMID: 8037246

42. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003; 27: 169–90. PMID: 12615092

43. Alemany S, Arias B, Aguiler M, Villa H, Moya J, Ibanez MI, et al. Childhood abuse, the BDNF-val66met polymorphism and adult psychotic-like experiences. Br J Psychiatry. 2011; 199: 38–42. doi: 10.1192/bjp.bp.110.083808 PMID: 21719879

44. Hernandez A, Gallardo-Pujol D, Pereda N, Arntz A, Bernstein DP, Gaviria AM, et al. Initial validation of the Spanish childhood trauma questionnaire-short form: factor structure, reliability and association with parenting. J Interpers Violence. 2013; 28: 1498–518. doi: 10.1177/0886260512468240 PMID: 23266990

45. Craske MG, Barlow DH. Mastery of your Anxiety and Panic. Therapist Guide. 4th ed. New York: Oxford University Press; 2007.

46. Prats E, Dominguez E, Rosado S, Pailhez G, Bulbena A, Fullana MA. Effectiveness of cognitive-behavioral group therapy for panic disorder in a specialized unit. Actas Esp Psiquiatr. 2014; 42: 176–84. PMID: 25017495

47. Muthén B. Latent variable mixture modeling. In: Marcoulides GA, Schumacker RE, editors. New Developments and Techniques in Structural Equation Modeling. Mahwah, NJ: Lawrence Erlbaum Associates; 2001. pp. 1–33.

48. Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in talent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007; 14: 535–69.

49. McLachlan G, Peel D. Finite mixture models. New York, NY: Wiley; 2004.

50. Lonsdorf TB, Weike AI, Golkar A, Schalling M, Hamm AO, Ohman A. Amygdala-dependent fear conditioning in humans is modulated by the BDNF-val66met polymorphism. Behav Neurosci. 2010; 124: 9–15. doi: 10.1037/a0018261 PMID: 20141278
51. Tietjen GE, Brandes JL, Peterlin BL, Eloff A, Dafer RM, Stein MR, et al. Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey. Headache. 2010; 50: 20–31. doi: 10.1111/j.1526-4610.2009.01556.x PMID: 19845782

52. Li X, Wang Z, Hou Y, Wang Y, Liu J, Wang C. Effects of childhood trauma on personality in a sample of Chinese adolescents. Child Abuse Negl. 2014; 38: 788–96. doi: 10.1016/j.chiabu.2013.09.002 PMID: 24161247

53. Schulz A, Schmidt CO, Appel K, Maher J, Spitzer C, Wingenfeld K, et al. Psychometric functioning, socio-demographic variability of childhood maltreatment in the general population and its effects of depression. Int J Methods Psychiatr Res. 2014; 23: 387–400. doi: 10.1002/mpri.24990306

54. Clark SL. Mixture modeling with behavioral data. Doctoral dissertation, University of California. 2010. Available: http://www.statmodel.com/download/Dissertation_v1.pdf

55. Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci. 2009; 29: 4056–64. doi: 10.1523/JNEUROSCI.5539-08.2009 PMID: 19339601

56. Notaras M, Hill R, van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry. 2015; 20: 86–70. doi: 10.1002/da.22430 PMID: 26647360

57. Labonte B, Suderman M, Maussion G, Navaro L, Yerko V, Mahar I, et al. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry. 2012; 69: 722–31. doi: 10.1001/archgenpsychiatry.2011.2287 PMID: 22752237

58. Naumova OY, Lee M, Koposov R, Szyf M, Dozier M, Grigorenko EL. Differential patterns of whole-genome DNA methylation in institutionalized children and children raised by their biological parents. Dev Psychopathol. 2012; 24: 143–55. doi: 10.1017/S0954579411000605 PMID: 22123582

59. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006; 187: 68–72. doi: 10.1007/s00221-005-2398-3

60. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry. 2010; 15: 810–5. doi: 10.1038/mp.2009.24 PMID: 19255578